Latest News and Press Releases

Fremont, CA, July 13, 2026 (GLOBE NEWSWIRE) -- Alamar Biosciences, Inc. (Nasdaq: ALMR), a leader in precision proteomics dedicated to advancing the early detection of disease, today announced a...

Fremont, CA, July 10, 2026 (GLOBE NEWSWIRE) -- Alamar Biosciences, Inc. (Nasdaq: ALMR), a leader in precision proteomics dedicated to enabling the earliest detection of disease, today announced that...

First gene replacement therapy in the EU for broad population with SMA, including children two years and older, teens and adults Fixed, one-time dose designed to replace the faulty SMN1 gene,...

Ad hoc announcement pursuant to Art. 53 LR FORTITUDE study met primary and key secondary endpoints of reduction in KHDC1L and creatine kinase levels, with safety profile consistent with previous...

Ecopipam, an investigational asset for pediatric Tourette syndrome (TS), is a first-in-class selective dopamine D1 receptor antagonist with a novel mechanism of action and has received FDA Orphan Drug...

CONNECTA Therapeutics initiates Phase IIa trial advancing treatments for rare CNS disorders, strengthening its clinical pipeline and development strategy.

NOON WORLD, the cognitive wellness brand redefining the functional gummy category, is now available in 878 Target stores nationwide.

Omniscient (o8t®) secures $27.2M Series D funding to scale its AI-powered Quicktome® brain mapping platform and accelerate personalized brain care globally

SYDNEY, May 28, 2026 (GLOBE NEWSWIRE) -- Actinogen Medical Limited (ASX: ACW) today announces the successful outcome of its scheduled scientific advice meeting (written response) on Alzheimer’s...

Synendos Therapeutics Starts Phase 2 Trial in Generalized Anxiety Disorder, marking the first time a SERI molecule is dosed in a patient population